Previous close | 51.59 |
Open | 51.30 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 51.30 - 51.68 |
52-week range | 37.18 - 69.06 |
Volume | |
Avg. volume | 79 |
Market cap | 45.783M |
Beta (5Y monthly) | 1.51 |
PE ratio (TTM) | 0.02 |
EPS (TTM) | 29.66 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Azenta, Inc. (Nasdaq: AZTA) today announced the grand opening of the new Genomics Laboratory in Oxford, UK, expanding its global reach of GENEWIZ Multiomics & Synthesis Solutions further in the UK market. The new laboratory brings Azenta closer to UK-based researchers, providing advanced next-generation sequencing (NGS) platforms and a local team of top-tier scientists from Oxford.
Revenue Surpasses Estimates, EPS Aligns with Projections
Azenta, Inc. (Nasdaq: AZTA) today announced a CEO succession plan, under which CEO and Board Director Dr. Stephen Schwartz will be retiring from Azenta after more than 14 years of service. Dr. Schwartz will continue to serve as CEO until a successor is appointed to ensure a smooth transition.